Trial · NCT03837626
ENAC Blockade and Arterial Stiffness
NCT03837626, Phase 2, Phase 3, Completed, University of Missouri-Columbia; results first posted 2025-12-30
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. ENAC Blockade and Arterial Stiffness. Trials, record NCT03837626. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03837626
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- ENAC Blockade and Arterial Stiffness
- NCT number
- NCT03837626
- Status
- Completed
- Phases
- Phase 2, Phase 3
- Enrollment
- 137 participants, actual
- Lead sponsor
- University of Missouri-Columbia
- Conditions
- Overweight and Obesity, Insulin Resistance
- Interventions
- Placebo - Cap, Amiloride Pill
- First posted
- 2019-02-12
- Last updated
- 2025-12-30
- Results first posted
- 2025-12-30
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Carotid Femoral Pulse Wave Velocity | baseline, 3 and 6 mo | cfPWV is the gold standard of arterial stiffness. It was assessd during experimental visits, under the same conditions in a blinded manner |
| Other | Systolic Blood Pressure | 3 and 6 mo | Systolic blood pressure obtained during experimental visits at the different time points |
| Other | Brachial Artery Flow Mediated Dilation (FMD) | Baseline, 3 months (interim) and 6 months (final) | Brachial artery flow-mediated dilation will be assessed at baseline, 12, and 24 weeks. FMD is a measurement of conduit artery endothelial function. |
| Other | Popliteal Artery Flow Mediated Dilation (FMD) | Baseline, 3 months (interim) and 6 months (final) | Popliteal artery flow-mediated dilation will be assessed at baseline, 12, and 24 weeks. FMD is a measurement of conduit artery endothelial function. |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| OTHER_PRE_SPECIFIED | Systolic Blood Pressure | 3 and 6 mo | mmHg | MEAN | |
| OTHER_PRE_SPECIFIED | Brachial Artery Flow Mediated Dilation (FMD) | Baseline, 3 months (interim) and 6 months (final) | Percentage | MEAN | |
| OTHER_PRE_SPECIFIED | Popliteal Artery Flow Mediated Dilation (FMD) | Baseline, 3 months (interim) and 6 months (final) | Percentage | MEAN | |
| PRIMARY | Carotid Femoral Pulse Wave Velocity | baseline, 3 and 6 mo | Number of participants that finished clinical trial | m/s | MEAN |
Source ClinicalTrials.gov
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Systolic Blood Pressure | Placebo | 3 mo | 127.53 | 95% Confidence Interval 123.07 to 132 | mmHg |
| Systolic Blood Pressure | Amiloride | 3 mo | 122.90 | 95% Confidence Interval 119.85 to 125.94 | mmHg |
| Systolic Blood Pressure | Placebo | 6 mo | 125.51 | 95% Confidence Interval 121.11 to 129.92 | mmHg |
| Systolic Blood Pressure | Amiloride | 6 mo | 120.27 | 95% Confidence Interval 117.25 to 123.30 | mmHg |
| Brachial Artery Flow Mediated Dilation (FMD) | Placebo | 3 months (interim) | 6.03 | 95% Confidence Interval 0.62 | Percentage |
| Brachial Artery Flow Mediated Dilation (FMD) | Amiloride | 3 months (interim) | 6.25 | 95% Confidence Interval 0.42 | Percentage |
| Brachial Artery Flow Mediated Dilation (FMD) | Placebo | Delta 6 months (final) | 5.59 | 95% Confidence Interval 0.56 | Percentage |
| Brachial Artery Flow Mediated Dilation (FMD) | Amiloride | Delta 6 months (final) | 6.16 | 95% Confidence Interval 0.44 | Percentage |
| Popliteal Artery Flow Mediated Dilation (FMD) | Placebo | 3 months (interim) | 1.71 | 95% Confidence Interval 0.30 | Percentage |
| Popliteal Artery Flow Mediated Dilation (FMD) | Amiloride | 3 months (interim) | 2.22 | 95% Confidence Interval 0.29 | Percentage |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Placebo | 47 | |
| Overall Study | STARTED | Amiloride | 90 | |
| Overall Study | COMPLETED | Placebo | 37 | |
| Overall Study | COMPLETED | Amiloride | 79 | |
| Overall Study | NOT COMPLETED | Placebo | 10 | |
| Overall Study | NOT COMPLETED | Amiloride | 11 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Headache | Nervous system disorders | Placebo | 5 | 47 | 5 |
| other | Headache | Nervous system disorders | Amiloride | 9 | 90 | 9 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Placebo | 0 | 47 |
| Total, all-cause mortality | Amiloride | 0 | 90 |
| Total, other adverse events | Placebo | 5 | 47 |
| Total, other adverse events | Amiloride | 9 | 90 |
| Total, serious adverse events | Placebo | 0 | 47 |
| Total, serious adverse events | Amiloride | 0 | 90 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Amiloride vs Placebo: deaths from any cause | Trial comparisons |
| Amiloride vs Placebo: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03837626
GET https://conductscience.org/api/trials/v1/NCT03837626/registered